ALBI Grade (Liver)ASTCT Grading ATA Thyroid Risk BCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPI CML ELTS Score CNS-IPI CTCAE v5.0 Calvert Formula DIPSS-Plus (Myelofibrosis)Deauville Score EAU NMIBC Risk ECOG Performance Status ELN 2022 Risk (AML)ELN CML Milestones FIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2 Fleischner 2017 Guidelines Fong Clinical Risk Score HCT-CI (Sorror Score)HPV/p16 Oropharynx IGCCCG Risk (Testicular)IMDC (Heng) Criteria IMWG Myeloma Frailty IPSS-M (Molecular MDS)ISUP Grade Groups Karnofsky Status (KPS)Khorana Score Lugano Classification Lung-RADS v2022 MIPI-b (Biological)MRD Assessment Framework MSI/MMR Interpretation Mayo 20/2/20 (SMM)NCCN Prostate Risk NCCN-IPI (DLBCL)NSCLC GPA Oncotype DX Recurrence Opioid Equianalgesic PD-L1 TPS Interpretation PERCIST 2.0 PREDICT v3.0 Platinum-Free Interval R2-ISS (Revised 2)RANO 2.0 RCB (Residual Cancer Burden)RECIST 1.1 ROMA Score SAVER Score SINS Score SLiM-CRAB Criteria Sedlis/Peters Criteria TNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AML Z0011 Eligibility iRECIST iwCLL 2018 Response mRECIST (HCC)mRENAL Score mrTRG (Rectal MRI)

Recent Journal Updates

DiabetologiaJun 8, 2026

Genetics of MASLD: a diabetes perspective

Clinical Context

We think this might be relevant to the clinical guidance for Minimal Residual Disease (MRD) Assessment.

Intensive Care MedicineJun 8, 2026

Patient blood management in general intensive care patients

Clinical Context

We think this might be relevant to the clinical guidance for Minimal Residual Disease (MRD) Assessment.

DiabetologiaJun 6, 2026

Time-restricted eating versus dietetic guidance on glycaemic outcomes in adults at risk of type 2 diabetes: a non-inferiority randomised clinical trial

Clinical Context

We think this might be relevant to the clinical guidance for Minimal Residual Disease (MRD) Assessment.

MRD Assessment Framework

MRD AssessmentMeasurable Residual Disease Framework

Assay Quantification

MRD Level% leukemic cells

*Interpret assay burden in the context of the platform used (Flow vs. NGS).

Awaiting Lab Data

Enter the Measurable Residual Disease (MRD) burden to see the standardized clinical interpretation.

MRD Thresholds

<0.01%: Below flow thresholds
0.01-0.09%: Low-level positivity
0.1-0.99%: Quantifiable positivity
>=1%: High-level residual disease

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Prognostication: Deeper remissions equal longer progression-free survival (PFS).

Treatment Adaptation: Escalating therapy (e.g., to allogeneic stem cell transplant or CAR-T) if MRD persists, or de-escalating/stopping therapy (e.g., fixed-duration venetoclax) if MRD is undetectable.

Early Relapse Detection: MRD conversion from negative to positive precedes overt clinical relapse, allowing for early, preemptive intervention.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the iwCLL 2018 Response, Ipss M Mds or the Who Icc 2022 Aml to formulate a comprehensive care plan.

Last Comprehensive Review: 2026